LA

PT UBC Medical Indonesia Tbk

LABS · JK · Healthcare / Medical Devices

129.00IDR+5.00 (+4.03%)

Price History

Full chart

Market Stats

Previous Close124.00
Open124.00
Day Range124.00 – 129.00
52-Week Range129.00 – 260.00
Volume1.48M
Market Cap576.70B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.21
50-Day Avg162.88
200-Day Avg151.67

About

PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoscholar, and Ina TB; QIAstat-DX Analyzer; and newborn screening products, including GSP Neonatal and Delfia Neonatal Kit, Neonatal Sampling Paper, and Victor2 D; and Care HPV System and Hybrid Capture 2 - HPV DNA Test. In addition, the company engages in the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and provision of chemical products and traditional medicine. It serves hospitals, clinical laboratories, and diagnostic centers, as well as central general hospitals, private hospitals, regional public hospitals, the ministry of health, and other ministries. The company was founded in 2014 and is based in Jakarta Timur, Indonesia. PT UBC Medical Indonesia Tbk is a subsidiary of PT Optel Investama Mulia.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Franciscus Xaverius Yoshua Raintjung
  • Employees54
  • HeadquartersKawasan Industri Pulogadung, Jakarta Timur, Indonesia, 13930, Indonesia
  • Websitehttps://ubcindonesia.com

Leadership

  • Mr. Franciscus Xaverius Yoshua RaintjungCorporate Secretary & President Director · b. 1979
  • Ms. Marcella AngelinDirector of Finance & Director · b. 1987
  • Muhammad Fajar ShodiqChief of Internal Audit Unit · b. 1995

Financials

Income Statement

Currency: IDR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue129.96B93.29B136.70B147.64B199.30B
Growth (%)--28.22%+46.53%+8.00%+34.99%
Cost of Revenue76.86B63.02B90.19B102.03B131.84B
Gross Profit53.10B30.27B46.51B45.61B67.46B
Gross Margin40.86%32.45%34.02%30.89%33.85%
Operating Expense49.91B26.88B40.66B36.66B47.09B
Operating Income3.19B3.40B5.84B8.95B20.37B
Operating Margin2.46%3.64%4.27%6.06%10.22%
EBITDA10.61B14.87B17.94B21.96B32.93B
EBITDA Margin8.17%15.94%13.13%14.87%16.52%
Net Income308.25M2.83B2.19B2.95B13.51B
Net Income Margin0.24%3.04%1.60%2.00%6.78%
Interest Expense112.31M1.55B2.15B3.04B1.25B
Interest Expense % of Total Revenue0.09%1.67%1.58%2.06%0.63%

Balance Sheet

Currency: IDR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets94.99B108.73B160.29B203.60B228.19B
Total Liabilities85.76B61.26B110.93B64.84B75.72B
Total Equity9.23B47.47B49.36B138.75B152.46B
Cash11.60B827.53M3.62B42.55B41.16B
Total Debt31.22B19.93B41.42B35.94B27.50B
Net Debt19.62B19.10B37.80B-6.61B-13.66B

Cash Flow

Currency: IDR2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-20.63B-15.05B-14.83B-13.68B22.89B
Investing Cash Flow-10.39B-5.04B-21.62B-6.85B-14.25B
Financing Cash Flow33.66B9.32B39.24B59.47B-10.03B
Capital Expenditure11.71B3.89B20.12B6.81B14.21B
Free Cash Flow-32.34B-18.94B-34.95B-20.49B8.68B
FCF to OCF156.76%125.87%235.68%149.78%37.92%

Key Statistics & Ratios

Market Cap576.70B
Enterprise Value691.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.77
Price / Book0.00
Book Value39.67
Revenue (TTM)207.82B
Gross Profit (TTM)85.10B
EBITDA32.17B
Profit Margin5.14%
Operating Margin11.58%
Return on Equity7.07%
Return on Assets5.98%
Shares Outstanding3.95B
Shares Float700.57M
Beta-0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%